Discover TEOXANE’s holistic approach to treat infraorbital hollows combining TEOSYAL ®  PURESENSE REDENSITY 2 & TEOSYAL RHA® 4

Ein ganzheitliches Konzept von TEOXANE zur Behandlung des infraorbitalen Volumenverlusts:

 

• TEOSYAL PureSenseRedensity® 2 – die erste und einzige injizierbare Hyaluronsäure, die speziell für die Behandlung von eingefallenen Augenpartien entwickelt wurde und seit 9 Jahren angewendet wird.1-4

• TEOSYAL RHA® 4  ein dynamischer und weicher Volumengeber in der Wangenregion5,6

• R[II] Eyes  eine leicht getönte Augenpflege als ideale Ergänzung und Fortsetzung der Behandlung zu Hause

Hinweis

1.Teoxane internal data source. Teosyal Redensity 2 deliveries from 2012 to 2020: 1'011'774 boxes

2.Berguiga et al. Orbit, 2017; 36(1):22-26.

3.TEOSYAL ® PURESENSE REDENSITY 2 – instruction for use

4.TEOXANE R&D report RDRE 2023. Data on File. Physical analysis of HA fillers intended for infraborbital uses. Torsion and compression tests assessed on a rheometer. The measurement of the rheological parameter Delta index represents the balance between gel viscosity and elasticity. . 

5.TEOSYAL RHA® 4 – instruction for use

6.RDRE 2015 - Rheological analysis of Volumizers _ Ultra Deep_RHA4_Lyft_Voluma

7. Michaud et al. J Cosmet Dermatol. 2015; 14(1): 9–21

8. Arcane Research Study conducted in France in March 2018 on 8.646 women from 18 to 75 y/o

9. Teoxane data source TEO-RHA-1902 Injection Guidelines

10. Funt. J Clin Aesthet Dermatol. 2011; 4(12):32-63

11. Bravo et al. J Clin Aesthet Dermatol. 2015; 8(6):30-5

12. Glaser et al. Dermatol Surg 2018; 44:1547-1554

13. Beleznay et al. Dermatol Surg. 2015; 41:1097-1117

14. Teoxane Post Market Surveillance data November 2020. 1445 practitioners worldwide

15. Ramanadham et al. Plast Reconstr Surg. 2015; 136:49S-55S

16.Teoxane Worldwide Survey "Periorbital Treatments in Clinics" by 180 injectors, June 2020

17. Cotofana et al. Facial Plast Surg. 2016; 32:253-260

18. Lemaire. E2e Medical Publishing, Master Collection 2, Paris, 2011

19. Kaufman-Janette et al. J Cosmet Dermatol. 2019; doi: 10.1111/jocd.1310

20. Rzany et al. Dermatol Surg; 2019; 45(10):1304-1314

21. TEOXANE Post-Marketing Surveillance from 2016 to 2020-Q3

22. Data on file 2020. Syneos study report 7010664.SA.259

23. Sharad. J Cutan Aesthet Surg. 2012; 5:229238

24. Sadick et al. Cosmet Dermatol. 2007;6(4):218-22

25. The properties of ingredients derive from data communicated by the raw material manufacturers

26.Efficacy study. Results measured after 28 days of use

 

* REDENSITY 2 = TEOSYAL® PureSense REDENSITY 2

# Depending on the country registration, TEOSYAL RHA® 4 exists in 1 mL

Find a practitioner

Required fields*

I agree to receive exclusive offers and the latest news from Hyaluronic-acid.com
Choose your country

Schließen

close
Europe

France

UK

Germany

Italy

Poland

Switzerland

Spain

Russia

International

English

French

Asia Pacific

Australia

Zurück zum Verbraucherbereich

Sie wechseln zum professionellen Bereich

close